Remission after CAR T‐cell therapy: Do lymphoma patients recover a normal life?
Authors:
Open Access
- 27 May 2024
- journal article
- research article
- Published by Wiley in HemaSphere
- Vol. 8 (5) , e72
Abstract
Chimeric antigen receptor T cells (CAR T cells) can induce prolonged remission in a substantial subset of patients with relapse/refractory lymphoma. However, little is known about patients' life after CAR T‐cell therapy. We prospectively assessed the multidimensional recovery of lymphoma patients in remission, before leukapheresis, before CAR T‐cell infusion, and 3, 6, and 12 months thereafter. Validated tools were used to measure lymphoma‐related and global health‐related quality of life (HRQoL; Functional Assessment of Cancer Therapy‐Lymphoma [FACT‐Lym] and EQ‐5D‐5L), cognitive complaint (FACT‐Cognition), fatigue (FACIT‐Fatigue subscale), psychological status (Hospital Anxiety and Depression Scale, Post‐Traumatic Check List Scale), and sexuality (Relationship and Sexuality Scale). Beyond 12 months of remission, we also surveyed physical, professional, sexual, and general life status. At 3, 6, and 12 months, 53, 35, and 23 patients were evaluable, respectively. Improvement in lymphoma‐related HRQoL was clinically relevant at 3, 6, and 12 months with a mean change from baseline of 10.9 (95% confidence interval [CI]: 5.8; 16.1), 12.2 (95% CI: 4.2; 20.1), and 11.72 (95% CI: 2.06; 21.38), respectively. Improvement in global HRQoL, fatigue, and anxiety was clinically relevant, but 20%–40% of patients experienced persistent fatigue, psychological distress, and cognitive complaints over time. Beyond 12 months after CAR T cells, 81.8% of 22 evaluable patients were satisfied with their daily life. Physical activity, professional, sexual, and global well‐being had returned to prediagnosis levels in nearly half of the patients. We found an improvement in HRQoL after CAR T‐cell therapy including anxiety, depression, sexual satisfaction, and general well‐being. However, not all patients recover a “normal life.” Further research is needed to determine which patients are at risk of quality‐of‐life impairment to improve recovery after CAR T‐cell infusion.Keywords
This publication has 61 references indexed in Scilit:
- Post-Traumatic Stress Symptoms in Long-Term Non-Hodgkin's Lymphoma Survivors: Does Time Heal?Journal of Clinical Oncology, 2011
- Sexual Well-Being Among Survivors of Non-Hodgkin LymphomaOncology Nursing Forum, 2011
- Normative values for the Hospital Anxiety and Depression Scale (HADS) in the general German populationJournal of Psychosomatic Research, 2011
- Estimation of minimally important differences in EQ-5D utility and VAS scores in cancerHealth and Quality of Life Outcomes, 2007
- Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important DifferencesEvaluation & the Health Professions, 2005
- [Evaluation of Post-traumatic Stress Disorder: validation of a measure, the PCLS].2003
- The F unctional A ssessment of C hronic I llness T herapy (FACIT) Measurement System: properties, applications, and interpretationHealth and Quality of Life Outcomes, 2003
- Combining Anchor and Distribution-Based Methods to Derive Minimal Clinically Important Differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue ScalesJournal of Pain and Symptom Management, 2002
- The Validation of the Posttraumatic Stress Disorder Checklist Scale in Posttraumatic Stress Disorder and Nonclinical SubjectsPsychotherapy and Psychosomatics, 2001
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983